197 related articles for article (PubMed ID: 34823564)
21. Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-κB.
Zhang DC; Liu JL; Ding YB; Xia JG; Chen GY
Acta Pharmacol Sin; 2013 Feb; 34(2):301-8. PubMed ID: 23274410
[TBL] [Abstract][Full Text] [Related]
22. A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance.
Vergara-Gómez L; Bizama C; Zhong J; Buchegger K; Suárez F; Rosa L; Ili C; Weber H; Obreque J; Espinoza K; Repetto G; Roa JC; Leal P; García P
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108401
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice.
Mita Y; Ajiki T; Kamigaki T; Okazaki T; Hori H; Horiuchi H; Hirata K; Fujita T; Fujimori T; Kuroda Y
Ann Surg Oncol; 2007 Apr; 14(4):1374-80. PubMed ID: 17235714
[TBL] [Abstract][Full Text] [Related]
24. aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.
Tian L; Lu Y; Yang T; Deng Z; Xu L; Yao W; Ma C; Li X; Zhang J; Liu Y; Wang J
Redox Biol; 2019 Apr; 22():101149. PubMed ID: 30822690
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Wagner AD; Buechner-Steudel P; Moehler M; Schmalenberg H; Behrens R; Fahlke J; Wein A; Behl S; Kuss O; Kleber G; Fleig WE
Br J Cancer; 2009 Dec; 101(11):1846-52. PubMed ID: 19904267
[TBL] [Abstract][Full Text] [Related]
26. YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation.
Bai X; Chen J; Zhang W; Zhou S; Dong L; Huang J; He X
Cancer Sci; 2023 Nov; 114(11):4299-4313. PubMed ID: 37700438
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic profiling of gallbladder cancer and gall stone diseases: Evaluation of role of tumour associated genes.
Singh TD; Gupta S; Shrivastav BR; Tiwari PK
Gene; 2016 Feb; 576(2 Pt 2):743-52. PubMed ID: 26456195
[TBL] [Abstract][Full Text] [Related]
28. The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.
Chen L; Wang Z; Xu Q; Liu Y; Chen L; Guo S; Wang H; Zeng K; Liu J; Zeng S; Yu L
Theranostics; 2020; 10(8):3562-3578. PubMed ID: 32206108
[No Abstract] [Full Text] [Related]
29. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin.
You MS; Ryu JK; Choi YH; Choi JH; Huh G; Paik WH; Lee SH; Kim YT
BMC Cancer; 2019 Jan; 19(1):10. PubMed ID: 30611225
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.
Gray SG; Baird AM; O'Kelly F; Nikolaidis G; Almgren M; Meunier A; Dockry E; Hollywood D; Ekström TJ; Perry AS; O'Byrne KJ
Int J Mol Med; 2012 Dec; 30(6):1505-11. PubMed ID: 23007409
[TBL] [Abstract][Full Text] [Related]
32. Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.
Mody K; Strauss E; Lincer R; Frank RC
BMC Cancer; 2010 Oct; 10():570. PubMed ID: 20961434
[TBL] [Abstract][Full Text] [Related]
33. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
34. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report.
Gallardo J; Fodor M; Gamargo C; Orlandi L
Cancer; 1998 Dec; 83(11):2419-21. PubMed ID: 9840543
[No Abstract] [Full Text] [Related]
36. DNA methylation of RUNX3 promotes the progression of gallbladder cancer through repressing SLC7A11-mediated ferroptosis.
Cai C; Zhu Y; Mu J; Liu S; Yang Z; Wu Z; Zhao C; Song X; Ye Y; Gu J; Sang Y; Wu X; Gong W
Cell Signal; 2023 Aug; 108():110710. PubMed ID: 37156453
[TBL] [Abstract][Full Text] [Related]
37. HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin.
Ruan Y; Wang L; Lu Y
Drug Dev Res; 2021 Jun; 82(4):598-604. PubMed ID: 33428788
[TBL] [Abstract][Full Text] [Related]
38. Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward.
Ostwal V; Swami R; Patkar S; Majumdar S; Goel M; Mehta S; Engineer R; Mandavkar S; Kumar S; Ramaswamy A
Med Oncol; 2018 Mar; 35(4):57. PubMed ID: 29564657
[TBL] [Abstract][Full Text] [Related]
39. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
40. DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.
Candelaria M; de la Cruz-Hernandez E; Taja-Chayeb L; Perez-Cardenas E; Trejo-Becerril C; Gonzalez-Fierro A; Chavez-Blanco A; Soto-Reyes E; Dominguez G; Trujillo JE; Diaz-Chavez J; Duenas-Gonzalez A
PLoS One; 2012; 7(3):e29181. PubMed ID: 22427797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
